Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is being developed at the Alewife Research Centre in Cambridge, Massachusetts, US.
Announced in July 2018, the new research facility will be housed in one of the world’s leading biotechnology clusters.
The $100m exploratory research facility aims to create next-generation medicines for Alzheimer’s disease (AD) and other dementias. It is a part of Eisai’s EWAY2025 mid-term strategy, which aims to use human genetics as a base to carry out studies related to dementia.
The new research facility is expected to commence operations in the first quarter of 2019. It will serve as a replacement for the Andover innovative Medicines (AiM) Institute, which is planned to be closed.
Eisai aims to discover and introduce compounds from the new facility by 2020. G2D2 is expected to have 70 employees once opened.
Location of Eisai’s G2D2 facility
G2D2 will be located in the Alewife Research Centre (ARC) at 35 Cambridge Park Drive in Cambridge, Massachusetts, US.
The ARC is a state-of-the-art Leadership in Energy and Environmental Design (LEED) Silver certified research facility being developed to provide flexible laboratory space and research and development (R&D) spaces for life science and pharmaceutical companies.
The Cambridge biotech hub was chosen to locate the new facility as it provides access to collaborations with research institutes and strategic partners. The location is expected to enhance partnerships with researchers and encourage open innovation initiatives and studies to promote immuno-dementia drug discovery.
The facility lies in close proximity to major private research organisations and academic institutions such as Harvard University, the Massachusetts Institute of Technology and Tufts University.
Facilities at Eisai Centre for Genetics Guided Dementia Discovery
G2D2 will span a 50,000ft² area. It will focus on R&D, creating new drug delivery systems and identifying next-generation dementia therapeutics to help patients and their caretakers.
The research centre will enable Eisai to focus on developing new approaches for drug discovery. It will use genetic information to control neural inflammation, which is the root cause of dementia combined with the accumulation of amyloid beta (Aβ) and tau in the blood.
The new facility will integrate various research milestones achieved by the AiM Institute in human genetics, neuro-biology, immune-biology and precision chemistry.
G2D2 will carry out genetic analysis of dementia and conduct studies focussed on neural inflammation using multiple proteins expressed on microglia as research targets. Its research focus will be grouped into data science, immuno-dementia biology, discovery science and chemistry.
Details of Eisai’s Andover innovative Medicines Institute
The AiM Institute is an innovation unit located within the Boston biopharma hub in Andover, Massachusetts.
The institute carries out research targetting key areas such as immuno-dementia, immuno-oncology and autoimmune indications.
The facility has 90 scientists carrying out research on novel therapeutic target validation studies on human genetics. It also develops precision medicines for certain difficult-to-treat medical conditions such as dementia, cancer and auto-immune diseases.
Marketing commentary on Eisai
Headquartered in Tokyo, Japan, Eisai is a pharmaceutical company dedicated to the discovery and development of pharmaceutical products in the areas of neurology, oncology, Alzheimer’s disease, epilepsy and metabolic disorders.
Eisai has been working to accumulate knowledge, create and discover new drugs in the area of dementia since 1983. The company began its research activities in the area of dementia at the Tsukuba Research Laboratories in Japan.
The company is working on accumulating data for the timely transformation of symptoms, immuno-dementia therapy and brain maintenance system. The pipeline products currently being researched and developed by Eisai include Aducanumab, Elenbecestat, BAN2401, Lemborexant, E2027 and E2814.
Catalent Biologics’ manufacturing facility in Anagni, Italy will serve as the launch facility for the large-scale production and supply of…
POINT Biopharma, a clinical-stage biopharmaceutical company, is planning to construct its first US manufacturing plant in Indianapolis, Indiana. The investment…